Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more
Location: 855 Oak Grove Avenue, Menlo Park, CA, 94025, United States | Website: https://orukatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
532.8M
52 Wk Range
$5.49 - $52.32
Previous Close
$14.07
Open
$13.93
Volume
91,928
Day Range
$13.93 - $14.37
Enterprise Value
74.49M
Cash
349.1M
Avg Qtr Burn
-20.95M
Insider Ownership
3.25%
Institutional Own.
86.54%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORKA-002 Details Psoriasis | Phase 1 Data readout |